HCV Infection., HCV Viral Load.
Conditions
Keywords
HCV, HIV, Nevirapine, HCV viral load, Efavirenz, Protease inhibitors
Brief summary
Nevirapine-based antiretroviral therapy is associated with lower plasma HCV viral load in HIV/HCV-coinfected individuals.
Interventions
DRUGNevirapine
nevirapine: 400 mg a day.
DRUGefavirenz, protease inhibitors
efavirenz: 600 mg a day
Sponsors
Boehringer Ingelheim
Valme University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* HIV infection. * Older than 18 years. * Chronic hepatitis C. * Undetectable HIV viral load during one year before starting study. * To have not received HCV therapy during one year before starting study. * To have not started efavirenz or protease inhibitors o nucleoside analogs during 6 months before starting study. * Non contraindications for drugs included in this study. * To change an antiretroviral regimen including efavirenz or protease inhibitors by nevirapine due to side effects, interactions or pregnancy (NVP group) * To continue with a antiretroviral regimen including efavirenz or protease inhibitors (non-NVP group) Both groups will be matched according to these variables: * Liver stiffness. * HCV genotype. * Hospital. * Time from starting antiretroviral therapy. * Previous third drug (EFV or PI) to introduction of NVP.
Exclusion criteria
* HCV therapy during follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in HCV viral load | 48 weeks |
Countries
Spain
Contacts
Primary ContactJOSE MIRA-ESCARTI, M.D
Outcome results
None listed